...oral HIF-PH inhibitor Vafseo from Akebia Therapeutics Inc. (NASDAQ:AKBA) and the NK1R antagonist Cinvanti from Heron Therapeutics Inc....

...The therapy is already approved as maintenance treatment of COPD. Heron PDUFA extended to June Heron Therapeutics Inc....
...furoate/vilanterol/umeclidinium, fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (GSK2834425) BioMarin Pharmaceutical Inc. Gilead Sciences Inc. Genfit S.A. Teva Pharmaceutical Industries Ltd. ForteBio Inc. Tocagen Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Immatics...

...terms are undisclosed (see "A Glympse at Drug Response" ). FDA accepts Heron NDA resubmission Heron Therapeutics Inc....
...NRG1 (HRG1) - Neuregulin 1; PDGFRα (PDGFR2; CD140A) - platelet derived growth factor receptor α BioCentury Staff HTX-011 MOR106 Heron Therapeutics Inc. GlaxoSmithKline...

...stock picker’s market in 4Q19 (see BioCentury’s 4Q19 Financial Markets Preview ). Heron raises $150M Heron Therapeutics Inc....
...quantifying eukaryotic RNA isolated from epithelial cells in stool. Elizabeth S. Eaton Innovent Biologics Inc. Oyster Point Pharma Inc. Heron Therapeutics Inc. Molecular...

...BSE:532296) FDA issues a complete response letter for Ryaltris mometasone/olopatadine to treat seasonal allergic rhinitis Heron Therapeutics Inc....

...Complete response letter for Heron’s non-opioid pain therapy Heron Therapeutics Inc. (NASDAQ:HRTX) was off $3.93 (18%) to $17.75...
...fosfomycin (Zolyd, ZTI-01) HTX-011 Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Alnylam Pharmaceuticals Inc. GlaxoSmithKline plc Heron Therapeutics Inc. Merck...

...cannabidiol Reduce seizure frequency in patients with tuberous sclerosis complex (TSC) Phase III data 2Q19 Heron Therapeutics Inc....

...precision therapy company said both will continue in their prior roles. Pain and cancer company Heron Therapeutics Inc....

...plc (NASDAQ:GWPH) Epidiolex cannabidiol Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome EC action 1Q19 Heron Therapeutics Inc....

...FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative...
...$2.19 to $25.94 on Dec. 31. Heron Therapeutics Inc. (NASDAQ:HRTX), San Diego, Calif. Product: HTX-011 Business: Neurology Jennie Walters HTX-011 Heron Therapeutics Inc....